Biohacker Network
PeptidesEvidence: Strong

Semaglutide: What a Peptide With Actual Evidence Looks Like

Written by
Maya Okafor, MS
Medically reviewed by
Dr. Sarah Lindqvist, MD
Published
June 20, 2025
Updated
June 20, 2025
Last medical review
June 20, 2025
Reviewer scope
Metabolic health
GLP-1 injection pen with blue cap — the FDA-approved once-weekly semaglutide delivery device backed by the STEP trial program

Semaglutide is a GLP-1 receptor agonist and the clearest example of what real peptide evidence looks like: large randomized trials showing roughly 15% mean weight loss over 68 weeks, cardiovascular outcome data, FDA approval for defined indications, and a well-characterized side-effect profile. It is prescription-only — and the FDA has specifically warned about adverse events with compounded versions sold outside that system.

The trial record in three lines

  • STEP 1: ~14.9% mean weight loss vs 2.4% placebo over 68 weeks in adults with obesity
  • SUSTAIN-6: cardiovascular safety signal favorable in type 2 diabetes
  • Common adverse events: GI (nausea, vomiting); boxed warning from rodent thyroid C-cell tumors
Balanced high-protein nutrition bowl — dietary strategy remains the base layer under any GLP-1 semaglutide prescription

Approved product vs compounded copies

The FDA has reported dosing errors and adverse events tied to compounded semaglutide, including products mixed with unapproved salt forms. The molecule’s evidence applies to the approved, quality-controlled product at labeled doses — not automatically to whatever a gray-market vial contains.

The compounded and novel-route market is where evidence goes missing — our sublingual drops review covers the newest format. For the fat-loss fragment that failed where semaglutide succeeded, see the AOD-9604 guide; for the field at a glance, the peptide cheat sheet; and for the full profile, our semaglutide monograph.

What discontinuation looks like

Extension data show substantial weight regain after stopping, which reframes semaglutide as chronic-disease management rather than a course of treatment. That conversation — indications, duration, exit strategy — belongs with a prescriber.

Frequently asked questions

How much weight do people lose on semaglutide?
In STEP 1, adults with obesity lost roughly 14.9% of body weight on average over 68 weeks versus 2.4% with placebo, alongside lifestyle intervention — the strongest weight-loss evidence of any peptide-class medication.
Is compounded semaglutide safe?
The FDA has specifically warned about adverse events and dosing errors with compounded semaglutide, including products using unapproved salt forms. The trial evidence applies to the approved, quality-controlled product at labeled doses.
What happens when you stop taking semaglutide?
Extension data show substantial weight regain after discontinuation, which reframes semaglutide as chronic-disease management rather than a finite course. Indications, duration, and exit strategy are prescriber conversations.

Questions to ask a licensed clinician

  • Do I meet approved criteria?
  • What is the titration and side-effect plan?
  • What happens when I stop?

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. SourcePhase-III RCT
  2. US Food and Drug Administration (2024). FDA's concerns with unapproved GLP-1 drugs used for weight loss. FDA Drug Alerts. SourceAgency notice

Related tools

Related guides

Something incorrect in this guide? Report a correction. Material corrections are noted on the page with the date and nature of the change.